Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067990 · ClinicalTrials.gov registry record · Phase 4
Angiotensin II Blockade for Chronic Allograft Nephropathy
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
NCT00067990 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 153 participants.
The verdict
NCT00067990, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
Study Summary
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.
Interventions
- DRUG Placebo
- DRUG Losartan 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2002-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067990
The ClinicalTrials.gov registry entry for NCT00067990 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00067990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067990 about?
NCT00067990 is a clinical study titled "Angiotensin II Blockade for Chronic Allograft Nephropathy". Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical ...
What is the current status of trial NCT00067990?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2002-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00067990?
The interventions under investigation include: Placebo (DRUG), Losartan 100mg (DRUG).
Who is sponsoring clinical trial NCT00067990?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.